About this trial
The current study aims to understand why some people with depression respond to treatment and others do not, using markers of clinical symptoms, both clinician reported outcome measures and patient reported outcome measures, demographic information, cognitive function, genetic sequence information (genomic), chemical measures of metabolism (metabolomic), protein makeup (proteomic) and the body's natural defence system (immune/inflammatory markers) together with collections of cells that will facilitate new research to drive improvements in diagnosis and treatment of mood disorders that may be proving difficult to treat. This will allow future clinical trials within the NHS, academia and industry to drive forward new approaches and treatments.
Participants who provide consent for re-contact for future treatment trials and other research studies have the potential to benefit from this with participation in experimental studies and clinical trials associated with improved patient outcomes. Overall, the cohort will generally support greater access to research opportunities for a wider population of people.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Those aged 18 and above
Primary clinical diagnosis of MDD or bipolar disorder based on DSM-5/ICD-11 diagnostic criteria
Participant is willing and able to give informed consent for participation in the study
Possesses sufficient command of the English language required to complete study requirements, as assessed by the study team
Disqualifiers
Inability to complete study activities as assessed by the study team
Presentation requires immediate emergency treatment
Presentation requires clinical input not available within the research clinic
Trial population
The current study aims to recruit adults aged 18 and over, currently residing in the UK with a diagnosis of major depressive disorder or bipolar disorder. The study will be advertised on social media and will allow people to self-refer to the study. We will also recruit via GP mail outs.
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
PHQ-9
Patient Health Questionnaire - 9-item Depression scale. Scores range between 0-27, with higher scores indicating worse depression.
Other outcomes
GAD-7
Generalised Anxiety Disorder Questionnaire - 7 item. Scores range between 0-21, with higher scores indicating worse anxiety.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Oxford
Lead sponsor
Newcastle University
Collaborator
University of Nottingham
Collaborator
University of Exeter
Collaborator
University of Southampton
Collaborator
University of Birmingham
Collaborator
University of Manchester
Collaborator
University of Liverpool
Collaborator
Avon and Wiltshire Mental Health Partnership NHS Trust
Collaborator
Cambridgeshire and Peterborough NHS Foundation Trust
Collaborator
University of Cambridge
Collaborator
Cardiff University
Collaborator
Cardiff and Vale University Health Board
Collaborator
University of Edinburgh
Collaborator
University of Glasgow
Collaborator
University College, London
Collaborator
Sheffield Health and Social Care NHS Foundation Trust
Collaborator
King's College London
Collaborator
Imperial College London
Collaborator
Oxford Health NHS FT
Collaborator
Cumbria, Northumberland, Tyne and Wear NHS FT
Collaborator
South London and Maudsley NHS FT
Collaborator
Nottinghamshire Healthcare NHS FT
Collaborator
Devon Partnership Trust
Collaborator
Hampshire and Isle of Wight Health NHS FT
Collaborator
Birmingham and Solihull Mental Health NHS Trust
Collaborator
Mersey Care NHS FT
Collaborator
NHS Lothian
Collaborator
NHS Greater Glasgow & Clyde
Collaborator
Camden & Islington NHS FT
Collaborator
West London NHS FT
Collaborator
Central and North West London NHS FT
Collaborator
This trial is not recruiting at the moment. You can still explore other options: